International Medical Information (IMI) is a medical publishing and medical information company with the distinct advantage of drawing upon the varied experience of its staff who have analytical, strategic, medical, marketing, project management, digital marketing, multimedia and creative skills.
Find all the latest news here. Why not register for further content on this and many other areas we cover.
Axsome Therapeutics announced that AXS 05 (bupropion + dextromethorphan) met key secondary endpoints in the STRIDE-1 trial by rapidly and statistically significantly improving symptoms of
Regeneron Pharma has presented Phase III ODYSSEY HoFH trial results from a late-breaking presentation, demonstrating the effect of Praluent (alirocumab) in patients with homozygous familial
Regeneron Pharmaceuticals announced that detailed Phase III ELIPSE HoFH trial results of REGN 1500 (evinacumab) in patients with homozygous familial hypercholesterolemia (HoFH). The data showed
The Dapagliflozin And Prevention of Adverse outcomes in Chronic Kidney Disease (DAPA-CKD) Phase III trial for Farxiga (dapagliflozin) in patients with chronic kidney disease (CKD)
Results from two subgroup analyses of the Phase IV independent TWILIGHT trial funded by AstraZeneca showed Brilinta (ticagrelor) monotherapy reduced the risk of clinically relevant
Eli Lilly and Company announced the FDA has approved a supplemental Biologics License Application (sBLA) for Taltz (ixekizumab) injection, 80 mg/mL for the treatment of
Copyright © ICR (UK) Limited t/a International Medical Information (IMI). Registered in the UK Company no. 05894351
medicalupdateonline.com is brought to you by International Medical Information. For more details, visit http://www.medicalimi.com
Disclaimer: All information on this site has been collated by healthcare professionals from around the globe. Where every possible step has been taken to ensure its accuracy, MedicalUpdateOnline cannot accept responsibility for the authenticity of the content matter.
Copyright: The copyright of the material on this site rests with the author unless otherwise indicated. It is a breach of copyright to use any material from this site without prior written consent.
